Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG 10% in primary immune thrombocytopenia (ITP)
CTR20200785Phase 3Completed
- Sponsor
- Guizhou Taibang Biological Products
- Start
- May 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immune globulin in immune thrombocytopenia (ITP), sponsored by Guizhou Taibang Biological Products. Primary endpoints: Platelet response within 7 days (≥30×10^9/L and ≥2× baseline) and Safety assessment. Started May 2020; status: completed.
02
Drugs
immune globulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20200785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200785.